Johnson & Johnson (JNJ) vs Eli Lilly and Company (LLY)
Johnson & Johnson and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $652.8B — 1.7× the size. Johnson & Johnson trades at the lower P/E: 31.4× against 39.7×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 8.06%. Eli Lilly and Company has the higher net margin (33.5% vs 21.5%) and the higher return on invested capital (26.3% vs 15.5%). Both pay a dividend; Johnson & Johnson yields more (3.07% vs 0.72%). Across the 23 metrics below, Johnson & Johnson leads on 12 and Eli Lilly and Company on 11.
Valuation
Profitability
| Metric | JNJ | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.91% | 83.40% | 72.77% |
| Operating margin | 27.69% | 42.22% | 18.90% |
| Net margin | 21.48% | 33.53% | 8.27% |
| Free cash flow margin | 23.20% | 22.83% | 17.25% |
| Return on equity | 25.74% | 102.29% | 6.97% |
| Return on assets | 10.67% | 21.97% | 2.76% |
| Return on invested capital | 15.51% | 26.33% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack